Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors

Sanchez-Martinez, D. ; Allende-Vega, N. ; Orecchioni, S. ; Talarico, G. ; Cornillon, A. ; Vo, D.N. ; Rene, C. ; Lu, Z.Y. ; Krzywinska, E. ; Anel, A. (Universidad de Zaragoza) ; Galvez, E.M. ; Pardo, J. (Universidad de Zaragoza) ; Robert, B. ; Martineau, P. ; Hicheri, Y. ; Bertolini, F. ; Cartron, G. ; Villalba, M.

Resumen: Monoclonal antibodies (mAbs) have significantly improved the treatment of certain cancers. However, in general mAbs alone have limited therapeutic activity. One of their main mechanisms of action is to induce antibody-dependent cell-mediated cytotoxicity (ADCC), which is mediated by natural killer (NK) cells. Unfortunately, most cancer patients have severe immune dysfunctions affecting NK activity. This can be circumvented by the injection of allogeneic, expanded NK cells, which is safe. Nevertheless, despite their strong cytolytic potential against different tumors, clinical results have been poor. Methods: We combined allogeneic NK cells and mAbs to improve cancer treatment. We generated expanded NK cells (e-NK) with strong in vitro and in vivo ADCC responses against different tumors and using different therapeutic mAbs, namely rituximab, obinutuzumab, daratumumab, cetuximab and trastuzumab. Results: Remarkably, e-NK cells can be stored frozen and, after thawing, armed with mAbs. They mediate ADCC through degranulation-dependent and -independent mechanisms. Furthermore, they overcome certain anti-apoptotic mechanisms found in leukemic cells. Conclusion: We have established a new protocol for activation/expansion of NK cells with high ADCC activity. The use of mAbs in combination with e-NK cells could potentially improve cancer treatment.

Idioma: Inglés

DOI: 10.7150/thno.25149

Año: 2018

Publicado en: THERANOSTICS 8, 14 (2018), 3856-3869
ISSN: 1838-7640

Factor impacto JCR: 8.063 (2018)

Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 10 / 135 = 0.074 (2018) - Q1 - T1

Factor impacto SCIMAGO: 2.176 - Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q1) - Medicine (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2014-54763-C2-1-R
Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2014-54763-C2-2-R
Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2017-83120-C2-1-R

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Inmunología (Dpto. Microb.Med.Pr.,Sal.Públ.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)